ZURICH (Reuters) - Roche Holding has agreed to buy long-term partner TIB Molbiol, a German biotech group, to enhance its portfolio of molecular diagnostics, the Swiss drugmaker said on Thursday, giving no financial terms for a deal set to close by year-end.
The acquisition will provide a wide range of assays forinfectious diseases, such as the identification of SARS-CoV-2 variants.
TIB Molbiol's portfolio of more than 45 CE-IVD assays and more than 100 research use assays is already available on Roche's LightCycler PCR systems and MagNA Pure sample preparation systems, it said here in a statement.
Reporting by Michael Shields; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.